--- a
+++ b/clusters/3009knumclusters/clust_289.txt
@@ -0,0 +1,207 @@
+Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
+Evidence of bleeding diathesis or clinically significant coagulopathy
+Patients with uncontrolled coagulopathy or bleeding disorder are not eligible
+Known bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is permitted, but patients must be on a stable dose.
+Evidence or history of bleeding diathesis or coagulopathy
+Participants with active bleeding disorder/coagulopathy
+History of coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+History of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or clinically significant coagulopathy.
+Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Bleeding disorder/coagulopathy
+Uncontrolled coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy
+No coagulopathy or bleeding diathesis
+Evidence of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of bleeding diathesis or coagulopathy
+History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).
+Uncontrolled coagulopathy or bleeding disorder
+Known coagulopathy or bleeding diathesis; those on therapeutic anticoagulation or anti-platelet agent are permitted only after discussing with the study PI
+Clinical evidence of bleeding diathesis or coagulopathy
+Patients with uncontrolled coagulopathy or bleeding disorder
+Evidence of bleeding diathesis or coagulopathy
+Patients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past year
+Evidence of bleeding diathesis or coagulopathy within 3 months (eg, von Willebrand’s disease or hemophilia.
+Uncontrolled coagulopathy
+(Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Active coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence or history of bleeding diathesis or coagulopathy
+Inherited bleeding diathesis or coagulopathy with the risk of bleeding
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Patients with uncontrolled coagulopathy or bleeding disorder
+uncorrectable coagulopathy
+Active coagulopathy
+Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs)
+REGORAFENIB EXCLUSION CRITERIA: Evidence or history of bleeding diathesis or coagulopathy
+History of or genetic predisposition to a bleeding diathesis or coagulopathy
+PHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
+PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anti-coagulation for prior thromboembolic events is permitted
+Evidence of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy
+Patients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past year
+Evidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing wound
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding
+Evidence of bleeding diathesis, coagulopathy as documented by an elevated PT, PTT or bleeding time
+Clinical evidence of bleeding diathesis or coagulopathy
+History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy (including clinically significant hemoptysis)
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of active bleeding diathesis or coagulopathy\r\n* For the NSCLC expanded cohort only: history of “blood tinged” sputum allowed
+No clinical evidence of hepatic failure (e.g. coagulopathy, ascites)
+Patients with uncontrolled coagulopathy or bleeding disorder
+Coagulopathy tests will be obtained within 2 weeks of enrollment
+Haemorrhagic diathesis (i.e. haemophilia)
+History of abnormal bleeding and coagulopathy
+Bleeding or evidence or history of clinically significant bleeding diathesis or coagulopathy within the last 3 months
+Clinically significant bleeding diathesis or coagulopathy
+Use of full dose, therapeutic anti-coagulation or patients with uncontrolled coagulopathy or bleeding disorder
+Uncontrolled coagulopathy
+History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
+Evidence or history of bleeding diathesis or coagulopathy
+Patients with a known coagulopathy or bleeding diathesis or require the use of systemic anticoagulant medication are not eligible
+Disseminated intravascular coagulopathy with active bleeding or signs of thrombosis
+Evidence of bleeding diathesis or coagulopathy
+Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy
+Patient has a coagulopathy or bleeding disorder
+Evidence or history of bleeding diathesis or coagulopathy
+Patients must not have a known bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents
+No significant bleeding within the past 6 months; no bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
+Evidence of bleeding diathesis or coagulopathy.
+Evidence of bleeding diathesis or coagulopathy
+Patients are excluded if they have evidence of bleeding diathesis or coagulopathy
+Known coagulopathy or bleeding disorders are controlled
+Evidence of bleeding diathesis or coagulopathy
+Known bleeding disorder or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
+Evidence or history of bleeding diathesis or coagulopathy.
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or coagulopathy within the past 6 months
+Evidence of bleeding diathesis or coagulopathy within 3 months
+Patients with a history of hemoptysis, bleeding diathesis, known platelet disorder, or coagulopathy are not eligible
+Known, existing uncontrolled coagulopathy
+Evidence of bleeding diathesis or clinically significant coagulopathy
+Evidence of prior or current coagulopathy or bleeding diathesis
+Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician
+Evidence or history of bleeding diathesis or coagulopathy
+Known, existing coagulopathy or receiving anticoagulants
+Patients must have no evidence of bleeding diathesis or coagulopathy; patients must have no pathologic condition other than mesothelioma that carries a high risk of bleeding
+Evidence or history of bleeding diathesis or coagulopathy
+Pre-existing bleeding diathesis, coagulopathy or hemorrhage
+Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
+The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding
+Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or clinically significant coagulopathy
+Evidence of bleeding diathesis or a clinically significant coagulopathy
+Patients with an active, bleeding diathesis or significant coagulopathy
+History of bleeding diathesis or coagulopathy. (Patients on stable anticoagulant therapy are eligible.)
+Patient has a coagulopathy or bleeding disorder which is uncontrolled.
+Evidence of bleeding diathesis or significant coagulopathy
+Patients with uncontrolled coagulopathy or bleeding disorder
+Evidence or history of bleeding diathesis or uncontrolled coagulopathy
+Evidence or history of a bleeding diathesis or coagulopathy, including therapy-induced coagulopathy
+Known, existing uncontrolled coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+History of coagulopathy or known thrombophilias
+Concurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathy
+Presence of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
+No known bleeding diathesis or coagulopathy
+Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia)
+Known, existing uncontrolled coagulopathy
+History of bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Known, existing uncontrolled coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+No history of clinical coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Coagulopathy or bleeding diathesis
+No known coagulopathy
+Patients must not have a known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
+Evidence of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy.
+Nonreversible or uncorrectable coagulopathy. INR should not be >1.5,
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Concurrent anticoagulation will be permitted providing the patient is receiving a stable dose of anticoagulants before study entry; patients receiving anticoagulants will be eligible for this trial; evidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g., INR > 1.5 without vitamin K antagonist therapy) will not be permitted
+Evidence of clinically significant bleeding diathesis or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation)
+Patients with uncontrolled coagulopathy or bleeding disorders
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Known bleeding disorder or coagulopathy
+Clinically significant coagulopathy or bleeding disorder.
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g. INR > 1.5 without vitamin K antagonist therapy), non-healing wound
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Patients must not have a bleeding diathesis, hereditary of acquired bleeding disorder or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+History of bleeding diathesis or coagulopathy other than that due to anticoagulation therapy
+Evidence or history of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy at the time of enrollment
+Evidence or history of bleeding diathesis or coagulopathy
+History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Any evidence of bleeding diathesis or coagulopathy
+Evidence or history of bleeding diathesis or coagulopathy
+Pre-existing coagulopathy
+Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
+Evidence or history of bleeding diathesis or coagulopathy
+Uncorrected coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Known bleeding diathesis or coagulopathy
+Subjects with uncorrected coagulopathy
+Uncorrectable coagulopathy
+Coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
+Evidence or history of bleeding diathesis or coagulopathy
+Patient has an uncorrectable coagulopathy
+Uncontrollable coagulopathy
+Coagulopathy
+Uncontrolled coagulopathy or bleeding disorders
+Known bleeding diathesis or coagulopathy
+History of coagulopathy or bleeding disorders
+Coagulopathy
+Known inherited bleeding disorder or coagulopathy
+Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) within 4 weeks of first study dose
+Severe coagulopathy or bleeding disorder
+Uncorrectable coagulopathy
+Uncorrectable coagulopathy
+Known coagulopathy
+Coagulopathy with platelets (Plt) < 10 k
+Patient must not have a known bleeding diathesis or coagulopathy
+Coagulopathy
+Evidence of a coagulopathy